Ubisoft’s share price looks bleak after its reset plan and big losses, but one recent deal suggests some of its biggest game series may be worth far more than the market is giving it credit for. The key is how much value sits inside its hit franchises and streaming rights—and whether restructuring, governance, and labor issues keep that value locked up.Read more

Atlas Salt is building a new underground salt mine near a port in Newfoundland, aiming to supply a steady, everyday product that cities rely on year after year. The big question is whether the company can lock in the funding to finish construction—because if it does, the market may have to rethink how risky this project really is.Read more

Berkshire Hathaway leans on a huge cash pile, low debt, and a long history of patient deal-making to hold up through rough markets and pounce on opportunities. The bigger question now is whether the handoff from Warren Buffett to Greg Abel keeps that steady approach working as the world changes.Read more

01 Quantum Inc. (formerly 01 Communique) has spent nearly a decade in quiet R&D, positioning itself as a first-to-market provider of software designed to protect the digital world from the existential threat of quantum computers.Read more

QuantumScape aims to make electric car batteries that can charge much faster, last longer, and be safer, using a new ceramic-based design that could change what drivers expect from an EV. The big question is whether it can reliably scale this lab-proven tech into mass production through its Volkswagen partnership before rivals catch up.Read more

Beam Therapeutics is betting that a newer, more precise form of gene editing can fix genetic diseases without the DNA damage risks tied to older approaches. Early human results in a liver-targeted program, plus a push to remove harsh chemotherapy from stem cell transplants, could open much larger patient groups—but competition and clinical execution still matter.Read more

IonQ claims it has crossed a key technical hurdle and now has the resources to push from lab promise toward real-world quantum machines. The big question is whether its room‑temperature approach and recent buyouts can turn into large deals with tech giants—or whether execution stumbles derail the story.Read more

Kodiak AI aims to sell self-driving capability to trucking fleets as a service, letting customers own the trucks while Kodiak provides the driving system and support. Big-name investors are buying in, but the company still faces a race to scale real-world driverless operations before it needs more funding—and shareholders could get watered down if it succeeds.Read more

Schrödinger blends drug research with powerful chemistry software used by many big pharmaceutical companies, creating a business that can fund its own next medicines. The near-term story hinges on upcoming trial results and new partnerships that could prove whether its approach can speed up discovery—or expose the usual drug-development setbacks.Read more